Vertex Pharmaceuticals Inc. shares rose after the biotech company said its drug to treat a kidney disorder met its goal in a ...

The drug maker says its treatment of a rare kidney disease met its main goal in a late-stage trial.

Vertex Pharmaceuticals said its drug for a rare kidney condition succeeded in a Phase 3 trial.

A new product approval may be right around the corner.

Company shares surged in after-market trading on results for a drug Vertex acquired in a multibillion-dollar deal and sees as having “best-in-class potential” in a competitive field.

These companies have impressive track records of navigating the biggest challenges in their industry.

Vertex said a drug it secured as part of a $4.9 billion acquisition successfully reduced by half a key marker of a kidney ...

Investing.com -- Vertex Pharmaceuticals (NASDAQ:VRTX) shares rose 6% to $488.52 in premarket trading Thursday after the ...

VRTX stock slips nearly 5% as concerns over new drug uptake and pipeline setbacks weigh, even as its dominant CF franchise continues to drive steady growth.

Vertex reported a phase 3 win for its kidney disease prospect povetacicept, meeting analyst expectations and firing the ...

Interim results from RAINIER reveal that an 80 mg dose of povetacicept every four weeks delivered a 52% reduction in protein ...